Does clomiphene in early pregnancy increase the risk of hypospadias?
Evidently not, according to a large, Danish, population-based, case–control study.
Evidently not, according to a large, Danish, population-based, case–control study.
Clomiphene, which is structurally related to diethylstilbestrol (DES), has been linked to urogenital anomalies and testicular cancer in males exposed in utero. In addition, hypospadias has been reported in boys born to women exposed to DES in utero.
But this latest study calculated an odds ratio of developing hypospadias after exposure to clomiphene of only 0.48 (95% CI; 0.15–1.54). Restricting exposure to clomiphene to the first trimester and up to 30 days prior to conception did not alter the result substantially.
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
